Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:
Canon Inc. manufactures and sells office multifunction devices. The Zacks Consensus Estimate for its current year earnings has been revised 26.7% downward over the last 30 days.
Douglas Emmett, Inc. (DEI - Free Report) is a fully integrated, self-administered and self-managed real estate investment trust. The Zacks Consensus Estimate for its current year earnings has been revised 6.1% downward over the last 30 days.
Eidos Therapeutics, Inc. is a clinical stage biopharmaceutical company. The Zacks Consensus Estimate for its current year earnings has been revised 7.4% downward over the last 30 days.
Regis Corporation (RGS - Free Report) owns, operates, and franchises hairstyling and hair care salons. The Zacks Consensus Estimate for its current year earnings has been revised 10.2% downward over the last 30 days.
Karuna Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Zacks Consensus Estimate for its current year earnings has been revised 34.5% downward over the last 30 days.
View the entire Zacks Rank #5 List.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:
Canon Inc. manufactures and sells office multifunction devices. The Zacks Consensus Estimate for its current year earnings has been revised 26.7% downward over the last 30 days.
Douglas Emmett, Inc. (DEI - Free Report) is a fully integrated, self-administered and self-managed real estate investment trust. The Zacks Consensus Estimate for its current year earnings has been revised 6.1% downward over the last 30 days.
Eidos Therapeutics, Inc. is a clinical stage biopharmaceutical company. The Zacks Consensus Estimate for its current year earnings has been revised 7.4% downward over the last 30 days.
Regis Corporation (RGS - Free Report) owns, operates, and franchises hairstyling and hair care salons. The Zacks Consensus Estimate for its current year earnings has been revised 10.2% downward over the last 30 days.
Karuna Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Zacks Consensus Estimate for its current year earnings has been revised 34.5% downward over the last 30 days.
View the entire Zacks Rank #5 List.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Get the latest research report on RGS - FREE
Get the latest research report on DEI - FREE